IL9 and interstitial lung disease: Thus, we can speculate that, at diagnosis, the histologic marker of lymphoid aggregates (LA), together with increased levels of tissue IL9 may help clinicians to better personalize pharmacological treatment and short-term surveillance for patients with fibrosing interstitial lung diseases.